Literature DB >> 19058140

Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions.

Unnati Jariwala1, Jon P Cogan, Li Jia, Baruch Frenkel, Gerhard A Coetzee.   

Abstract

BACKGROUND: The androgen receptor (AR) plays roles in prostate development and cancer (PCa). In response to androgens, the AR binds to androgen-response elements (AREs) to modulate gene transcription. The responses of such genes are dependent on the cellular milieu and on sequences around the AREs, which attract other transcription factors. Previously, bioinformatic analysis of 62 AR-occupied regions (ARORs) in PCa cells revealed enrichment for both AREs and a TTGGCAAATA-like motif. We undertook the present study to investigate the significance of the TTGGCAAATA-like motif.
METHODS: Prostate cancer cell lines, LNCaP and C4-2B, were analyzed by transient transfections of wild-type and mutant reporter constructs, electro-mobility shift assays (EMSAs), and RT-qPCR analysis of endogenous genes.
RESULTS: In two of six tested ARORs, point mutations in the TTGGCAAATA-like motif resulted in inhibition of DHT-mediated enhancer activity. EMSA revealed that Oct1 bound the motif, and that the mutations that abolished DHT responsiveness in the transfection assays augmented Oct1 binding. These results suggest a role for Oct1 as a context-dependent negative coregulator of AR. Consistent with this, siRNA knockdown of Oct1 increased the DHT-mediated enhancer activity of transfected reporters as well as an endogenous AR target gene, transglutaminase 2.
CONCLUSIONS: Oct1 negatively regulates DHT-mediated enhancer activity in a subset of ARORs. The enrichment of ARORs for the Oct-binding, TTGGCAAATA-like motif may reflect a mechanism that utilizes Oct1 to keep AR activity in check at some ARORs, while augmenting AR activity in other ARORs. Therefore, Oct1 may have regulatory functions in prostate development and cancer progression. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19058140      PMCID: PMC2743387          DOI: 10.1002/pros.20893

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  35 in total

Review 1.  The virtuoso of versatility: POU proteins that flex to fit.

Authors:  K Phillips; B Luisi
Journal:  J Mol Biol       Date:  2000-10-06       Impact factor: 5.469

2.  Differential dimer activities of the transcription factor Oct-1 by DNA-induced interface swapping.

Authors:  A Reményi; A Tomilin; E Pohl; K Lins; A Philippsen; R Reinbold; H R Schöler; M Wilmanns
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

3.  Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1.

Authors:  M I Gonzalez; D M Robins
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

Review 4.  Differential activity by DNA-induced quarternary structures of POU transcription factors.

Authors:  Attila Reményi; Alexey Tomilin; Hans R Schöler; Matthias Wilmanns
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

5.  Androgen receptor interactions with Oct-1 and Brn-1 are physically and functionally distinct.

Authors:  M Ivelisse González; Alessandra Tovaglieri; Diane M Robins
Journal:  Mol Cell Endocrinol       Date:  2002-04-25       Impact factor: 4.102

6.  Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb.

Authors:  Jason E Boehm; Ugra Singh; Carolyn Combs; Marc A Antonyak; Richard A Cerione
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

Review 7.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

Review 8.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

Review 9.  Contribution of the androgen receptor to prostate cancer predisposition and progression.

Authors:  G Buchanan; R A Irvine; G A Coetzee; W D Tilley
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

10.  Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity.

Authors:  Li Jia; Benjamin P Berman; Unnati Jariwala; Xiting Yan; Jon P Cogan; Allison Walters; Ting Chen; Grant Buchanan; Baruch Frenkel; Gerhard A Coetzee
Journal:  PLoS One       Date:  2008-11-10       Impact factor: 3.240

View more
  5 in total

1.  Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.

Authors:  D Obinata; K Takayama; K Fujiwara; T Suzuki; S Tsutsumi; N Fukuda; H Nagase; T Fujimura; T Urano; Y Homma; H Aburatani; S Takahashi; S Inoue
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

2.  Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer.

Authors:  Ruth Perets; Tommy Kaplan; Ilan Stein; Guy Hidas; Shay Tayeb; Eti Avraham; Yinon Ben-Neriah; Itamar Simon; Eli Pikarsky
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

3.  Elevated OCT1 participates in colon tumorigenesis and independently predicts poor prognoses of colorectal cancer patients.

Authors:  Yu-Peng Wang; Guo-He Song; Jian Chen; Chao Xiao; Chao Li; Lin Zhong; Xing Sun; Zhao-Wen Wang; Gui-Long Deng; Fu-Dong Yu; Ying-Ming Xue; Hua-Mei Tang; Zhi-Hai Peng; Xiao-Liang Wang
Journal:  Tumour Biol       Date:  2015-10-04

Review 4.  Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer.

Authors:  Daisuke Obinata; Kenichi Takayama; Satoru Takahashi; Satoshi Inoue
Journal:  Cancers (Basel)       Date:  2017-02-28       Impact factor: 6.639

5.  High expression of octamer transcription factor 1 in cervical cancer.

Authors:  Songshu Xiao; Shan Liao; Yanhong Zhou; Bin Jiang; Yueran Li; Min Xue
Journal:  Oncol Lett       Date:  2014-04-02       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.